193 related articles for article (PubMed ID: 25877716)
1. The ubiquitin-proteasome pathway an emerging anticancer strategy for therapeutics: a patent analysis.
Jain CK; Arora S; Khanna A; Gupta M; Wadhwa G; Sharma SK
Recent Pat Anticancer Drug Discov; 2015; 10(2):201-13. PubMed ID: 25877716
[TBL] [Abstract][Full Text] [Related]
2. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
3. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
4. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
5. Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials.
Nabavi SF; Atanasov AG; Khan H; Barreca D; Trombetta D; Testai L; Sureda A; Tejada S; Vacca RA; Pittalà V; Gulei D; Berindan-Neagoe I; Shirooie S; Nabavi SM
Cancer Lett; 2018 Oct; 434():101-113. PubMed ID: 30030139
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
7. Regulation of apoptosis proteins in cancer cells by ubiquitin.
Zhang HG; Wang J; Yang X; Hsu HC; Mountz JD
Oncogene; 2004 Mar; 23(11):2009-15. PubMed ID: 15021888
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
10. Role of the ubiquitin proteasome system in hematologic malignancies.
Sahasrabuddhe AA; Elenitoba-Johnson KS
Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
[TBL] [Abstract][Full Text] [Related]
11. E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway.
Woo SM; Kwon TK
BMB Rep; 2019 Feb; 52(2):119-126. PubMed ID: 30638181
[TBL] [Abstract][Full Text] [Related]
12. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development.
Tsukamoto S; Yokosawa H
Curr Med Chem; 2006; 13(7):745-54. PubMed ID: 16611064
[TBL] [Abstract][Full Text] [Related]
13. [The ubiquitin-proteasome proteolytic pathway and tumorigenesis].
Li YF; Zhang Q; Zhu DH
Yi Chuan; 2006 Dec; 28(12):1591-6. PubMed ID: 17138548
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ubiquitin E1 as a novel anti-cancer strategy.
Xu W; Lukkarila JL; da Silva SR; Paiva SL; Gunning PT; Schimmer AD
Curr Pharm Des; 2013; 19(18):3201-9. PubMed ID: 23151135
[TBL] [Abstract][Full Text] [Related]
16. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.
Ao N; Chen Q; Liu G
Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
Inoue T; Shiraki K; Fuke H; Yamanaka Y; Miyashita K; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Anticancer Drugs; 2006 Mar; 17(3):261-8. PubMed ID: 16520654
[TBL] [Abstract][Full Text] [Related]
18. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway.
Ohoka N; Nagai K; Hattori T; Okuhira K; Shibata N; Cho N; Naito M
Cell Death Dis; 2014 Nov; 5(11):e1513. PubMed ID: 25375378
[TBL] [Abstract][Full Text] [Related]
19. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Kitagawa K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
[TBL] [Abstract][Full Text] [Related]
20. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Mooneyham A; Bazzaro M
Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
